Amneal Resubmits New Drug Application for Migraine Treatment, Diabetes Drug Is Approved

By MarketWatch | Nov 21, 2024 at 05:05 PM EST

Amneal Pharmaceuticals resubmitted a migraine treatment application and received approval for a diabetes and obesity treatment from the FDA. The company's new ready-to-use migraine treatment and GLP-1 agonist were highlighted for their benefits.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.